

Financial news for NPSP dated on 2015-02-23: NPS Pharma Shares Halted with Code 'For Info'

Financial news for NPSP dated on 2015-02-21: Shire Completes Acquisition of NPS Pharma

Financial news for NPSP dated on 2015-02-17: 3 Niche ETFs Breaking Out

Financial news for NPSP dated on 2015-02-03: Wedbush Weighs In On Medivation Following Phase II TERRAIN Study Results

Financial news for NPSP dated on 2015-01-24: NPS Pharmaceuticals Announces FDA Approves Natpara

Financial news for NPSP dated on 2015-01-15: 10 Biotech Stories You Might've Missed This Week

Financial news for NPSP dated on 2015-01-13: UPDATE: Barclays Capital Downgrades NPS Pharmaceuticals After Announced Acquisition By Shire

Financial news for NPSP dated on 2015-01-13: Barclays Downgrades NPS Pharmaceuticals to Equal-weight, Lowers PT to \$46.00

Financial news for NPSP dated on 2015-01-12: Mid-Day Market Update: Foundation Medicine Shares Jump Following Deal With Roche; Crude Oil Slides Over 4%

Financial news for NPSP dated on 2015-01-12: Mid-Morning Market Update: Markets Tumble; Shire To Acquire NPS Pharmaceuticals For \$5.2 Billion

Financial news for NPSP dated on 2015-01-12: What The Market's Reading: January 12

Financial news for NPSP dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

Financial news for NPSP dated on 2015-01-12: Benzinga's Volume Movers

Financial news for NPSP dated on 2015-01-12: Morning Market Losers

Financial news for NPSP dated on 2015-01-12: Morning Market Gainers

Financial news for NPSP dated on 2015-01-12: UPDATE: Jefferies Raises Price Target On NPS Pharmaceuticals Ahead Of Acquisition By Shire

Financial news for NPSP dated on 2015-01-12: Benzinga's Top Downgrades

Financial news for NPSP dated on 2015-01-12: Benzinga's Top #PreMarket Losers

Financial news for NPSP dated on 2015-01-12: Benzinga's Top #PreMarket Gainers

Financial news for NPSP dated on 2015-01-12: Canaccord Genuity Downgrades NPS Pharmaceuticals To Hold

Financial news for NPSP dated on 2015-01-12: US Stock Futures Signal Higher Start On Wall Street

Financial news for NPSP dated on 2015-01-12: Canaccord Genuity Downgrades NPS Pharmaceuticals to Hold, Maintains \$42.00 PT

Financial news for NPSP dated on 2015-01-12: NPS Pharmaceuticals Shares Rise 8% Premarket on Announcement of Deal to be Acquired by Shire

Financial news for NPSP dated on 2015-01-12: Canaccord Genuity Downgrades NPS Pharmaceuticals to Hold, Maintains \$42.00 PT

Financial news for NPSP dated on 2015-01-12: Must Watch Stocks for January 12, 2015

Financial news for NPSP dated on 2015-01-11: Benzinga's Weekend M&A Chatter

Financial news for NPSP dated on 2015-01-11: UPDATE: Shire to Acquire NPS Pharma for \$46.00/Share

Financial news for NPSP dated on 2015-01-11: Shire To Acquire NPS Pharmaceuticals for \$5.2 Billion

Financial news for NPSP dated on 2015-01-07: What Investors Should Expect From Rockwell Medical's Next FDA Decision

Financial news for NPSP dated on 2015-01-07: NPS Pharmaceuticals Is In Overbought Territory: What's Next?

Financial news for NPSP dated on 2015-01-06: What Investors Are Looking For In NPS Pharmaceuticals Ahead Of A Potential Sale

Financial news for NPSP dated on 2015-01-06: UPDATE: Barclays Capital Initiates Coverage On NPS Pharmaceuticals Ahead Of Natpara Launch

Financial news for NPSP dated on 2015-01-06: Barclays Initiates Coverage on NPS Pharmaceuticals at Overweight, Announces \$50.00 PT

Financial news for NPSP dated on 2015-01-05: Benzinga's M&A Chatter for Monday January 5, 2015

Financial news for NPSP dated on 2015-01-05: Report: NPS Pharmaceuticals Headed For Block

Financial news for NPSP dated on 2015-01-05: NPS Pharmaceuticals Declines Comment on Report it May be for Sale

Financial news for NPSP dated on 2015-01-05: UPDATE: Sources Say Goldman Sachs Advising NPS Pharmaceuticals on Sale, Could Bring \$4.5B

Financial news for NPSP dated on 2015-01-05: NPS Pharmaceuticals Seeks Buyer, According to Sources -DJ

Financial news for NPSP dated on 2015-01-05: NPS Pharmaceuticals Shares Spike Higher

Financial news for NPSP dated on 2015-01-02: New Biotech ETF From ALPS

Financial news for NPSP dated on 2014-12-17: Benzinga's M&A Chatter for Wednesday December 17, 2014

Financial news for NPSP dated on 2014-12-17: NPS Pharmaceuticals Spikes 19% Amid Shire Bid Report

Financial news for NPSP dated on 2014-12-17: Ian Estepan@ianestepan Tweet: \$SHPG also says that they are reviewing other targets - most logical other target \$FOLD

Financial news for NPSP dated on 2014-12-17: Shares of NPS Pharma Resume, Now Up 16.5%

Financial news for NPSP dated on 2014-12-17: UPDATE: Shares of NPS Pharma Halted Up ~12%

Financial news for NPSP dated on 2014-12-17: NPS Pharma Spikes Higher

Financial news for NPSP dated on 2014-12-17: Shares of NPS Pharma Halted on Circuit Breaker as Bloomberg Reporting Shire Considering Bid for Co.

Financial news for NPSP dated on 2014-12-02: NPS Pharma Announces The European Medicines Agency Validates Marketing Authorization Application For Its Natpar

Financial news for NPSP dated on 2014-11-24: NPS Pharmaceuticals' Teduglutide Granted Orphan Drug Designation In Japan

Financial news for NPSP dated on 2014-11-10: NPS Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.02) vs \$0.02 Est; Revenue of \$57.20M vs \$59.75M Est

Financial news for NPSP dated on 2014-10-24: Morning Market Losers

Financial news for NPSP dated on 2014-10-24: Benzinga's Top #PreMarket Losers

Financial news for NPSP dated on 2014-10-23: NPS Pharmaceuticals Announces PDUFA Date For Natpara Extended To Jan. 24, 2015

Financial news for NPSP dated on 2014-10-22: Option Alert: NPS Pharmaceuticals Nov \$36 Call; 1,229 Contract Trade at Ask @\$2.10; Currently \$28.35

Financial news for NPSP dated on 2014-10-20: Bank Of America Q3 Small & Mid-Cap Biotech Preview

Financial news for NPSP dated on 2014-10-19: Benzinga's Weekend M&A Chatter

Financial news for NPSP dated on 2014-10-19: Shire Reportedly in Takeover Talks with Cubist, NPS Pharmaceuticals, According to Sources -The Telegraph

Financial news for NPSP dated on 2014-09-15: Technology Stocks Down As Rest Of The Market Starts Week Flat

Financial news for NPSP dated on 2014-09-15: Terex Falls After Lowered Earnings Forecast; Avanir Pharmaceuticals Shares Surge

Financial news for NPSP dated on 2014-09-15: NASDAQ Tumbles 1.1%; Alere Shares Surge Following Proposed \$46/Share Offer

Financial news for NPSP dated on 2014-09-15: Markets Fall; Cognizant To Acquire TriZetto For \$2.7 Billion

Financial news for NPSP dated on 2014-09-15: Morning Market Losers

Financial news for NPSP dated on 2014-09-15: Benzinga's Top #PreMarket Losers

Financial news for NPSP dated on 2014-09-12: FDA Votes 8-5 in Favor of NPS Pharmaceuticals' Natpara

Financial news for NPSP dated on 2014-09-12: US Stock Futures Flat Ahead Of Economic Data

Financial news for NPSP dated on 2014-09-12: NPS Pharmaceuticals, Inc. Stock Trading Halted Today; FDA Advisory Committee to Review Natpara Biologics License Application

Financial news for NPSP dated on 2014-09-10: Stocks Gain As Oil, Euro Continue Sharp Sell Off

Financial news for NPSP dated on 2014-09-10: Lands' End Jumps On Strong Quarterly Earnings; GT Advanced Technologies Shares Slide

Financial news for NPSP dated on 2014-09-10: U.S. Stocks Rise; Palo Alto Networks Shares Surge On Upbeat Revenue

Financial news for NPSP dated on 2014-09-10: Markets Edge Lower; Krispy Kreme Doughnuts Profit Misses Estimates

Financial news for NPSP dated on 2014-09-10: Benzinga's Volume Movers: 21Vianet Group Inc, NPS Pharmaceuticals & More

Financial news for NPSP dated on 2014-09-10: Morning Market Movers

Financial news for NPSP dated on 2014-09-10: FDA Posts Briefing Materials For Advisory Committee Meeting Reviewing Natpara For Hypoparathyroidism

Financial news for NPSP dated on 2014-09-10: FDA Issues Staff Review on NPS Pharma's Natpara

Financial news for NPSP dated on 2014-09-04: NPS Pharmaceutical Shares Move Higher; Hearing Chatter of Possible Strong Investor Reaction to Natpra FDA Documents Next Week

Financial news for NPSP dated on 2014-08-13: Option Alert: NPS Pharma Sep \$30 Call; 5,114 Contracts Traded vs 321 OI; Currently \$26.64

Financial news for NPSP dated on 2014-08-06: NPS Pharmaceuticals, Inc. Reports Q2 EPS of \$0.02 vs \$0.00 Est; Revenue of \$56.13M vs \$53.06M Est. On Track To Hit Guidance

Financial news for NPSP dated on 2014-08-04: NPS Pharma Initiates Phase 2a Study Of NPSP795 In Adult Patients With Autosomal Dominant Hypocalcemia (ADH)

Financial news for NPSP dated on 2014-08-04: NPS Pharma Announces Initiation of Phase 2a Study of NPSP795

Financial news for NPSP dated on 2014-06-30: NPS Pharma Announces FDA Approval of Updated Gattex Labeling

Financial news for NPSP dated on 2014-06-18: NPS Pharmaceuticals Spikes Higher

Financial news for NPSP dated on 2014-06-16: NPS Pharmaceuticals Spikes Lower on Volume

Financial news for NPSP dated on 2014-06-10: NPS Pharma Announces Change in Tentative Date for FDA AdCom to Sept. 12th, Oct. 24th PDUFA Date Remains Unch

Financial news for NPSP dated on 2014-06-06: NPS Pharmaceuticals Spikes Higher on Volume

Financial news for NPSP dated on 2014-06-02: Form 8-K from NPS Pharma Shows Board Confirmation Mgmt Has Not Held Talks with Shire

Financial news for NPSP dated on 2014-06-02: Mid-Afternoon Market Update; ISM Revised

Twice, CONN Maintains Gains On Earnings Report

Financial news for NPSP dated on 2014-06-02: Mid-Day Market Update: MasTec Tumbles On Weak Forecast; Protective Life Shares Spike Higher

Financial news for NPSP dated on 2014-06-02: Mid-Morning Market Update: Markets Fall; Conn's Profit Beats Street View

Financial news for NPSP dated on 2014-06-02: Benzinga's Volume Movers

Financial news for NPSP dated on 2014-06-02: Morning Market Movers

Financial news for NPSP dated on 2014-06-02: NPS Pharmaceuticals Shoots Up 20 Percent On Rumor

Financial news for NPSP dated on 2014-06-02: Benzinga's Top #PreMarket Gainers

Financial news for NPSP dated on 2014-06-02: UPDATE: NPS Pharmaceuticals Trading 13% Higher Premarket Following Friday's Rumored Bid from Shire

Financial news for NPSP dated on 2014-05-30: Mid-Afternoon Market Update; Big Lots EPS Beat & Increases Guidance

Financial news for NPSP dated on 2014-05-30: Mid-Day Market Update: Express Drops On Weak Results; OmniVision Shares Jump

Financial news for NPSP dated on 2014-05-30: Shire Considering Cash Bid For NPS Pharmaceuticals?

Financial news for NPSP dated on 2014-05-30: Mid-Morning Market Movers

Financial news for NPSP dated on 2014-05-30: FT Reporting Shire Could Be Considering Cash Bid for NPS Pharma

Financial news for NPSP dated on 2014-05-30: UPDATE: Move in NPS Pharmaceuticals May be Attributed to Positive Comments from CEO on Gattex

Financial news for NPSP dated on 2014-05-30: NPS Pharmaceuticals Spikes Higher

Financial news for NPSP dated on 2014-05-22: Earlier Janney Capital Initiated Coverage on NPS Pharmaceuticals, Inc. at Buy, Announces \$37.00 PT

Financial news for NPSP dated on 2014-05-08: Mid-Afternoon Market Update: Markets Turn Back As SolarCity Hangs Onto Gains

Financial news for NPSP dated on 2014-05-08: Mid-Day Market Update: Keurig Green Mountain Jumps On Upbeat Earnings; Tesla Shares Slide

Financial news for NPSP dated on 2014-05-08: Mid-Morning Market Update: Markets Gain; Wendy's Profit Beats Street View

Financial news for NPSP dated on 2014-05-08: Morning Market Losers

Financial news for NPSP dated on 2014-05-08: NPS Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.06) vs \$(0.02) Est; Revenue of \$44.0M vs \$48.26M Est

Financial news for NPSP dated on 2014-04-16: UPDATE: Canaccord Genuity Assumes Coverage on NPS Pharmaceuticals on Recent Market Weakness

Financial news for NPSP dated on 2014-03-25: Benzinga's Top Initiations

Financial news for NPSP dated on 2014-03-25: Goldman Sachs Initiates Coverage on NPS Pharmaceuticals, Inc. at Buy, Announces \$45.00 PT

Financial news for NPSP dated on 2014-02-19: UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

Financial news for NPSP dated on 2014-02-19: Jefferies Downgrades NPS Pharmaceuticals, Inc. to Hold, Maintains \$38.00 PT

Financial news for NPSP dated on 2014-02-18: NPS Pharmaceuticals, Inc. Reports Q4 EPS of \$0.07 vs \$0.02 Est; Revenue of \$54.50M vs \$44.38M Est

Financial news for NPSP dated on 2014-02-10: New Hope for Families of Children with a Rare Life-Threatening Disorder

Financial news for NPSP dated on 2014-01-08: Market Wrap For January 8: Fed Minutes Released

Financial news for NPSP dated on 2014-01-08: NPS Pharma Reports Prelim. 2013 Net Global Sales \$31.5M, Sees 2014 Gattex/Revestive Sales \$110-120M

Financial news for NPSP dated on 2014-01-07: NPS Pharma Wins FDA Acceptance of Biologics License

Financial news for NPSP dated on 2014-01-03: NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara by EC

Financial news for NPSP dated on 2014-01-02: NPS Pharma Begins Global Registration Study of Teduglutide in Kids, Expecting to Close Study in Late 2014, Early 2015

Financial news for NPSP dated on 2013-11-13: NPS Pharma Reports FDA Acceptance of sNDA for Gattex, Sees FDA Action by Jun. 28th, 2014

Financial news for NPSP dated on 2013-11-06: Mid-Afternoon Market Update: Markets Mixed as Tesla Shares Remain Down

Financial news for NPSP dated on 2013-11-06: Brean Capital Upgrades NPS Pharmaceuticals, Inc. to Buy

Financial news for NPSP dated on 2013-11-06: NPS Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.01) vs \$(0.02) Est; Revenue of \$39.20M vs \$38.40M Est

Financial news for NPSP dated on 2013-10-24: NPS Pharma Submits BLA for Natpara in Hypoparathyroidism

Financial news for NPSP dated on 2013-10-14: NPS Pharma Says Data from STEPS 2 Trial of Gattex Supports Long-Term Use

Financial news for NPSP dated on 2013-10-11: Mid-Afternoon Market Update: Markets Green as Spirit Airlines Soars

Financial news for NPSP dated on 2013-10-11: Mid-Day Market Update: Micron Shares Tumble On Downbeat Profit; SolarCity Spikes Higher

Financial news for NPSP dated on 2013-10-11: Mid-Morning Market Update: Markets Rise; JPMorgan Posts Upbeat Core Earnings

Financial news for NPSP dated on 2013-10-07: NPS Pharma Says 53% of Natpara-Treated Patients Achieved Primary Endpoint

Financial news for NPSP dated on 2013-10-03: UPDATE: Bank of America Initiates Coverage on NPS Pharmaceuticals as Gattex and Natpara Could Provide Meaningful Annuities

Financial news for NPSP dated on 2013-10-03: Benzinga's Top Initiations

Financial news for NPSP dated on 2013-10-03: Bank of America Initiates Coverage on NPS Pharmaceuticals, Inc. at Buy, Announces \$46.00 PO

Financial news for NPSP dated on 2013-10-02: NPS Pharma Says sNDA Submitted for Gattex STEPS 2 Data, Shows Sustained Effects

Financial news for NPSP dated on 2013-09-20: UPDATE: J.P. Morgan Initiates Coverage on NPS Pharmaceuticals on Emerging Market Leader Status

Financial news for NPSP dated on 2013-09-20: Benzinga's Top Initiations

Financial news for NPSP dated on 2013-09-20: JP Morgan Initiates Coverage on NPS Pharmaceuticals, Inc. at Overweight, Announces \$40.00 PT

Financial news for NPSP dated on 2013-09-11: NPS Pharmaceuticals CEO Nader: 'We are Initiating Gattex in the Pediatric Population'

Financial news for NPSP dated on 2013-09-11: NPS Pharmaceuticals CEO Nader: 'We Don't Need to Raise Cash '

Financial news for NPSP dated on 2013-09-11: NPS Pharmaceuticals CEO Nader: 'We are Happy with the Launch of Gattex, But Looking Toward the Future'

Financial news for NPSP dated on 2013-09-11: Jim Cramer Interviews CEO Dr. Francois Nader of NPS Pharmaceuticals on Mad Money

Financial news for NPSP dated on 2013-09-11: Report NPS Pharmaceuticals to Appear on Made Money Tonight

Financial news for NPSP dated on 2013-08-21: UPDATE: Oppenheimer Raises PT on NPS Pharmaceuticals Following Gattex Survey

Financial news for NPSP dated on 2013-08-09: Market Wrap for Friday, August 9: Stocks Close Lower To End Week

Financial news for NPSP dated on 2013-08-08: NPS Pharma Files Automatic Mixed Securities Shelf

Financial news for NPSP dated on 2013-08-08: NPS Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.16) Which May Not Compare \$(0.07) Est; Revenue of \$36.51M Which May Not Compare \$31.62M Est

Financial news for NPSP dated on 2013-06-21: NPS Pharma to Issue Update on Gattex Launch, Sees 200-300 Patients by Yearend, Confirms Prior View

Financial news for NPSP dated on 2013-05-28: NPS Pharma Announces Exercise of Over-Allotment Option, Sees Net Proceeds \$93.4M

Financial news for NPSP dated on 2013-05-28: NPS Pharmaceuticals Announces Exercise of Over-Allotment Option and Closing of Public Offering

Financial news for NPSP dated on 2013-05-22: Mid-Afternoon Market Update: MannKind Posts Huge Rally as Markets Plummet

Financial news for NPSP dated on 2013-05-22: Mid-Day Market Update: Dycom Gains On Upbeat Results, CVR Partners Drops

Financial news for NPSP dated on 2013-05-21: NPS Pharma Prices 6M Shares at \$14.53/Share, Sees Gross Proceeds ~\$87.2M

Financial news for NPSP dated on 2013-05-20: NPS Pharma Announces 6M Share Common Stock Offering

Financial news for NPSP dated on 2013-05-10: S&P Highlights Biotech ETFs

Financial news for NPSP dated on 2013-05-09: NPS Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.09) vs \$(0.13) Est; Revenue of \$25.43M vs \$27.56M Est

Financial news for NPSP dated on 2013-04-24: UPDATE: Oppenheimer Initiates NPS Pharmaceuticals with Outperform on Leading Assets

Financial news for NPSP dated on 2013-04-23: Oppenheimer Initiates Coverage on NPS Pharmaceuticals, Inc. at Outperform, Announces \$18.00 PT

Financial news for NPSP dated on 2013-03-20: UPDATE: Wedbush Raises PT on NPS Pharmaceuticals on Rights Buyback

Financial news for NPSP dated on 2013-03-20: UPDATE: Jefferies Raises PT on NPS Pharmaceuticals on Regained Product Rights

Financial news for NPSP dated on 2013-03-20: Jefferies Maintains Buy on NPS Pharmaceuticals, Inc., Raises PT to \$16.00

Financial news for NPSP dated on 2013-03-19: NPS CEO Nader: 'Orphan Diseases are our Business, So the International Rights for Gattex Made Sense for Us'

Financial news for NPSP dated on 2013-03-19: NPS CEO Nader: 'We are Fixing the Manufacturing Issues with our Osteoporosis Drug'

Financial news for NPSP dated on 2013-03-19: NPS CEO Nader: We're Very Excited by the Potential of Natpara'

Financial news for NPSP dated on 2013-03-19: Jim Cramer Interviews CEO Dr. Francois Nader of NPS Pharmaceuticals on Mad Money

Financial news for NPSP dated on 2013-03-19: Market Wrap for Tuesday, March 19: Dow Records Slight Gain, Nasdaq and S&P Close Lower

Financial news for NPSP dated on 2013-03-19: Mid-Afternoon Market Update: Copper Continues to Take a Beating, Lattice Semiconductor Rallies

Financial news for NPSP dated on 2013-03-19: Mid-Day Market Update: Markets Turn Red, DSW Declines On Downbeat View

Financial news for NPSP dated on 2013-03-19: Brean Capital Downgrades NPS Pharmaceuticals, Inc. to Hold

Financial news for NPSP dated on 2013-03-19: Benzinga's Volume Movers

Financial news for NPSP dated on 2013-03-19: Mid-Morning Market Update: Markets Turn

Green, Electronic Arts CEO Steps Down

Financial news for NPSP dated on 2013-03-19: Morning Market Movers

Financial news for NPSP dated on 2013-03-19: A Peek Into The Market Before The Trading Starts

Financial news for NPSP dated on 2013-03-19: NPS Pharmaceuticals Re-Gains Full Worldwide Rights to Teduglutide

Financial news for NPSP dated on 2013-01-07: NPS CEO Nader: 'It's Important to Remember it's Not About the Price of the Product, It's About the Quality of Life Gattex Allows'

Financial news for NPSP dated on 2013-01-07: NPS CEO Nader: 'Gattex is in the Middle of the Fairway in Orphan Drug Pricing'

Financial news for NPSP dated on 2013-01-07: NPS CEO Nader: 'There is a Premium for Treating Only 3,000 to 5,000 Patients'

Financial news for NPSP dated on 2013-01-07: Jim Cramer Interviews CEO Dr. Francois Nader of NPS Pharmaceuticals on Mad Money

Financial news for NPSP dated on 2012-12-27: NPS Pharma's Gattex Picked by Providers to Support Distribution, Home-Based Clinical Care Services

Financial news for NPSP dated on 2012-12-21: FDA Approves NPS Gattex for Injection for Some SBS Patients

Financial news for NPSP dated on 2012-12-21: NPS Pharma Shares Moving Lower Amid FDA Approval of Gattex

Financial news for NPSP dated on 2012-12-21: NPS Pharma Wins FDA Approval for Gattex in Bowel Syndrome

Financial news for NPSP dated on 2012-12-21: NPS Pharmaceuticals Spikes Higher

Financial news for NPSP dated on 2012-11-29: NPS Pharma Publishes Pivotal Phase 3 Study of Gattex in Short Bowel Syndrome Patients

Financial news for NPSP dated on 2012-11-09: NPS Pharmaceuticals Reports Q3 EPS \$-0.04 vs \$-0.16 Est; Revenues \$27.02M vs \$28.18M Est

Financial news for NPSP dated on 2012-10-22: NPS Pharmaceuticals Reports Data On Gattex Study

Financial news for NPSP dated on 2012-10-18: Benzinga Mid-Afternoon Market Update

Financial news for NPSP dated on 2012-10-18: Benzinga Mid-Day Market Update

Financial news for NPSP dated on 2012-10-18: Benzinga Mid-Morning Market Update

Financial news for NPSP dated on 2012-10-17: UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on NPS Pharmaceuticals

Financial news for NPSP dated on 2012-10-17: Jefferies & Company Maintains NPS Pharmaceuticals at Buy, Raises PT from \$13 to \$15

Financial news for NPSP dated on 2012-10-16: NPS Pharmaceuticals Falls 3% Following Positive FDA Panel Vote

Financial news for NPSP dated on 2012-10-16: PREVIEW: NPS Pharmaceuticals to Resume at 4:20pm

Financial news for NPSP dated on 2012-10-16: FDA Unanimously Recommends Approval of Gattex (teduglutide) for Adults with Short Bowel Syndrome (SBS)

Financial news for NPSP dated on 2012-10-16: UPDATE: NPS Pharma Wins FDA Panel Backing for Gattex; Says Benefits Outweigh Risks

Financial news for NPSP dated on 2012-10-16: FDA Advisory Panel Votes 12-0 in Favor of NPS Pharma's Gattex

Financial news for NPSP dated on 2012-10-16: Benzinga Mid-Day Market Update

Financial news for NPSP dated on 2012-10-16: FDA Advisory Committee to Review NPS Pharmaceuticals' Gattex New Drug Application

Financial news for NPSP dated on 2012-10-16: NPS Pharmaceuticals Halted; Pending News

Financial news for NPSP dated on 2012-10-15: Benzinga Mid-Day Market Update

Financial news for NPSP dated on 2012-10-15: Benzinga Mid-Morning Market Update

Financial news for NPSP dated on 2012-10-12: Benzinga Mid-Afternoon Market Update

Financial news for NPSP dated on 2012-10-12: Benzinga Mid-Morning Market Update

Financial news for NPSP dated on 2012-10-12: FDA Staff Says NPS Short Bowel Drug Gattex Deemed to Work; Supports NPS Pharma's Risk Plan For Short Bowel Drug Gattex; Panel to Meet October 16 to Discuss Drug -Bloomberg

Financial news for NPSP dated on 2012-10-04: UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight on Portfolio Quality

Financial news for NPSP dated on 2012-10-03: Options Alert: NPS Pharmaceuticals

Financial news for NPSP dated on 2012-10-03: Morgan Stanley Initiates Coverage on NPS Pharmaceuticals at Overweight, Announces PT of \$17

Financial news for NPSP dated on 2012-09-28: Friday September 28th Watchlist

Financial news for NPSP dated on 2012-09-19: Benzinga's Top Pre-Market Gainers

Financial news for NPSP dated on 2012-09-05: NPS Pharma Expects to File Natpara BLA in Mid 2013

Financial news for NPSP dated on 2012-09-04: Revestive Receives European Marketing Authorization for the Treatment of Adults with Short Bowel Syndrome

Financial news for NPSP dated on 2012-08-21: NPS Pharma Says Gattex Meeting October 16th

Financial news for NPSP dated on 2012-08-13: Benzinga's Top Pre-Market Losers

Financial news for NPSP dated on 2012-08-13: NPS Pharma NDA Extended to December 30

Financial news for NPSP dated on 2012-08-13: NPS Pharmaceuticals Announces Extension of Action Date for Gattex NDA to December 30, 2012

Financial news for NPSP dated on 2012-08-01: NPS Pharmaceuticals Reports Q2 EPS \$0.08 vs \$-0.09 Est; Revenues \$53.5M vs \$25.68M Est

Financial news for NPSP dated on 2012-07-18: Biotechs With Upcoming PDUFA Dates

Financial news for NPSP dated on 2012-07-09: UPDATE: Wedbush Increases PT to \$18 on NPS Pharmaceuticals Post Amended Sensipar Agreement

Financial news for NPSP dated on 2012-07-09: Wedbush Securities Maintains NPS Pharmaceuticals at Outperform, Raises PT from \$17 to \$18

Financial news for NPSP dated on 2012-07-02: NPS Pharmaceuticals Resumes Trading

Financial news for NPSP dated on 2012-07-02: PREVIEW: NPS Pharmaceuticals to Resume Trading at 9:00am

Financial news for NPSP dated on 2012-07-02: NPS Pharmaceuticals Announces Amended Royalty Agreement with Amgen

Financial news for NPSP dated on 2012-06-27: Wedbush Securities Maintains NPS Pharmaceuticals at Outperform, Raises PT from \$14 to \$17

Financial news for NPSP dated on 2012-06-27: BMO Capital Markets Reiterates Market Perform Rating, \$5 PT for NPS Pharmaceuticals

Financial news for NPSP dated on 2012-06-25: New Findings from REPLACE Study Support Potential of Natpara(TM) to Treat Adult Hypoparathyroidism

Financial news for NPSP dated on 2012-06-22: Social Media Outlook for Friday June 22 (DRI, NPSP, R, GS)

Financial news for NPSP dated on 2012-06-22: Benzinga's Top Pre-Market Gainers

Financial news for NPSP dated on 2012-06-22: Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive(r)) for Patients with Short Bowel Syndrome

Financial news for NPSP dated on 2012-06-22: Committee for Medicinal Products for Human Use Grants Marketing Authorization for Revestive

Financial news for NPSP dated on 2012-06-18: NPS Pharmaceuticals Reports Natpara™ Phase 3 Results to be Presented at ENDO, the annual meeting of The Endocrine Society

Financial news for NPSP dated on 2012-05-03: NPS Pharmaceuticals Reports Four Additional Patients Achieve Independence from Parenteral Support in STEPS 2 Study of Gattex(r) in Adult Short Bowel Syndrome

Financial news for NPSP dated on 2012-02-15: NPS Pharmaceuticals Reports Q4 EPS \$(0.10) vs \$(0.09) Est; Revenues \$26.26M vs \$26.17M Est

Financial news for NPSP dated on 2012-01-31: Benzinga's Top Pre-Market Gainers

Financial news for NPSP dated on 2012-01-31: NPS Pharmaceuticals Announces FDA Acceptance of New Drug Application for GATTEX

Financial news for NPSP dated on 2012-01-10: Notable Call Options Activity in NPS Pharmaceuticals

Financial news for NPSP dated on 2011-12-01: NPS Pharmaceuticals Completes Submission of New Drug Application for GATTEX in Adult Short Bowel Syndrome

Financial news for NPSP dated on 2011-11-10: NPS Pharmaceuticals CFO Luke Bshar Buys 20K Shares at \$5.36

Financial news for NPSP dated on 2011-11-07: Notable Call Options Activity in NPS Pharmaceuticals

Financial news for NPSP dated on 2011-11-07: NPS Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase 3 REPLACE Study of NPSP558 in Hypoparathyroidism

Financial news for NPSP dated on 2011-11-01: Brean Murray Carret & Co Maintain Buy Rating and \$14 PT on NPS Pharmaceuticals

Financial news for NPSP dated on 2011-10-31: End-of-Day Market Summary for October 31, 2011

Financial news for NPSP dated on 2011-10-31: Top Movers; Sify Technologies up 30%

Financial news for NPSP dated on 2011-10-31: Citigroup on NPS Pharmaceuticals: Cancer Cases Result of Quality Issues, Not Approval

Financial news for NPSP dated on 2011-10-31: UPDATE: NPS Pharma Reports Deaths in Bowel Drug Trial -Reuters

Financial news for NPSP dated on 2011-10-31: NPS Pharmaceuticals Hits New 52-Week Low, \$4.84, Down 37%

Financial news for NPSP dated on 2011-10-31: Phase 3 GATTEX Data Highlight Potential New Treatment for Adults with Short Bowel Syndrome

Financial news for NPSP dated on 2011-10-05: UPDATE: Stifel Nicolaus Initiates NPS Pharmaceuticals at Buy

Financial news for NPSP dated on 2011-10-05: Stifel Nicolaus Initiates NPS Pharmaceuticals at Buy, \$11 PT

Financial news for NPSP dated on 2011-08-22: Afternoon Loser; Velti Down Nearly 13%

Financial news for NPSP dated on 2011-08-18: NPS Pharmaceuticals Submits Chemistry, Manufacturing and Controls Section of New Drug Application for GATTEX

Financial news for NPSP dated on 2011-08-15: NPS Pharmaceuticals Announces Amended Amgen Agreement and Plan to Retire Sensipar-Backed Series B Notes

Financial news for NPSP dated on 2011-08-11: Calls Purchased on NPS Pharmaceuticals

Financial news for NPSP dated on 2011-08-02: NPS Pharmaceuticals Announces New Calcilytics Agreement with GlaxoSmithKline

Financial news for NPSP dated on 2011-05-10: GATTEX(R) (teduglutide) Shown to Reduce Parenteral Support Volume in Patients with Adult Short Bowel Syndrome (NPSP)

Financial news for NPSP dated on 2011-05-03: NPS Pharma Reports 1Q EPS of \$(0.13) vs. \$(0.12) Estimate.

Financial news for NPSP dated on 2011-04-28: Brean Murray Reiterates Buy Rating On NPSP

Financial news for NPSP dated on 2011-04-19: NPS Pharmaceuticals Announces Closing of \$107M Public Offering

Financial news for NPSP dated on 2011-04-14: Benzinga's Top Pre-Market NASDAQ Gainers (SNTS, NPSP, HGSI, GOLD)

Financial news for NPSP dated on 2011-04-11: NPS Pharmaceuticals Announces Public Offering of 9M Shares

Financial news for NPSP dated on 2011-03-28: NPS Pharmaceuticals Partner Submits Application to Market Teduglutide in Europe

Financial news for NPSP dated on 2011-03-28: Jefferies Reports On NPS Pharmaceuticals Study (NPSP)

Financial news for NPSP dated on 2011-03-16: Jefferies Reiterates Buy on NPS Pharmaceuticals (NPSP)

Financial news for NPSP dated on 2011-03-01: NPS Pharmaceuticals Completes Patient Randomization in Phase 3 REPLACE Study of NPSP558

Financial news for NPSP dated on 2011-02-15: NPS Pharmaceuticals Reports Q4 EPS of \$(0.09) vs. \$(0.20)

Financial news for NPSP dated on 2011-01-31: NASDAQ Stocks Hitting 52-Week Highs (CLDA, DEPO, CPSI, NPSP)

Financial news for NPSP dated on 2011-01-31: Options Brief: NPS Pharmaceuticals (NPSP)

Financial news for NPSP dated on 2011-01-31: Morning Market Movers (DEPO, NPSP, ZNWA, OREX)

Financial news for NPSP dated on 2011-01-31: Benzinga's Top Pre-Market NASDAQ Gainers (DEPO, NPSP, GERN, XNPT)

Financial news for NPSP dated on 2011-01-31: NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) News; GATTEX (teduglutide) Meets Primary Efficacy Endpoint in Phase 3 Pivotal Study in Patients with Adult Short Bowel Syndrome

Financial news for NPSP dated on 2011-01-31: NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) News; GATTEX (teduglutide) Meets Primary Efficacy Endpoint in Phase 3 Pivotal Study in Patients with Adult Short Bowel Syndrome

Financial news for NPSP dated on 2011-01-18: Calls Purchased on NPS Pharmaceuticals (NPSP)

Financial news for NPSP dated on 2011-01-14: NPS Pharma Readies Key Bowel Study Data

Financial news for NPSP dated on 2011-01-10: NPS Pharmaceuticals Announces Completion of Treatment Phase in STEPS Registration Study of GATTEX

Financial news for NPSP dated on 2010-09-21: NPS Pharmaceuticals Announces Closing of \$47.5 Million Public Offering

Financial news for NPSP dated on 2010-09-16: Benzinga's Top Pre-Market NASDAQ Losers (NPSP, ERIC, VOD, SVNT)

Financial news for NPSP dated on 2010-09-15: NPS Pharmaceuticals Announces Proposed \$41 Million Public Offer

Financial news for NPSP dated on 2010-08-04: NPS Pharmaceuticals Reports Second Quarter Financial Results

Financial news for NPSP dated on 2010-06-01: NPS Pharmaceuticals to Present at Two Upcoming Conferences (NPSP)

Financial news for NPSP dated on 2010-04-07: NPSP Initiated At Needham

Financial news for NPSP dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?